Drug

BGM0504 Delivers Up to 19.2% Weight Loss in Phase III at EASD 2026 – CR Sanjiu and BrightGene's GLP‑1/GIP Dual Agonist Meets All Endpoints in Chinese Population
BrightGene Bio-Medical TechnologyChina Resources Sanjiu Medical & Pharmaceutical

BGM0504 Delivers Up to 19.2% Weight Loss in Phase III at EASD 2026 – CR Sanjiu and BrightGene’s GLP‑1/GIP Dual Agonist Meets All Endpoints in Chinese Population

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SHE: 000999) and BrightGene Bio‑Medical Technology Co., Ltd. (SHA: 688166) announced that Phase III clinical study results for BGM0504 injection, a GLP‑1/GIP…

Centergate's Subsidiary Shandong Huasu Receives NMPA Clinical Trial Approval for BDB Tablets – Novel Combination Antihypertensive Enters Clinical Development

Centergate’s Subsidiary Shandong Huasu Receives NMPA Clinical Trial Approval for BDB Tablets – Novel Combination Antihypertensive Enters Clinical Development

Zhongsheng's ZSP1601 Granted Breakthrough Therapy Designation by China's CDE – First‑in‑Class MASH Drug with Positive Phase IIb Data Enters Accelerated Review

Zhongsheng’s ZSP1601 Granted Breakthrough Therapy Designation by China’s CDE – First‑in‑Class MASH Drug with Positive Phase IIb Data Enters Accelerated Review

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CancerClinical trial approval / initiation

Leads Biolabs’ Opamtistomig Becomes World’s First 4-1BB Bispecific Antibody to Enter Pivotal Phase III for EP-NEC

CancerClinical trial approval / initiation

CSPC Pharmaceutical Receives NMPA Clinical Trial Approval for SYH2095, World’s First KAT6 Inhibitor

Boehringer Ingelheim's JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis
Boehringer IngelheimProduct approvals

Boehringer Ingelheim’s JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis

Bayer's HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment
BayerETR: BAYN

Bayer’s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment

Show More